Pliant reports positive Phase 2a data for bexotegrast in PSC; 320 mg well tolerated up to 40 weeks

PLIANT THERAPEUTICS, INC.

320 mg cohort met primary safety endpoint; no treatment-related severe or serious adverse events.
Improvement in liver stiffness by transient elastography at Week 24 vs placebo.
Statistically significant reduction in alkaline phosphatase (ALP) over 24 weeks vs placebo.
MRI showed continued improvement in hepatocyte function and bile flow from Week 12 to 24.
FDA supportive of 52-week Phase 2b trial with non-invasive endpoints; program path being evaluated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.